Media headlines about Pacific Biosciences of California (NASDAQ:PACB) have trended positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a media sentiment score of 0.34 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.5887921464241 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Several brokerages have recently issued reports on PACB. CL King cut Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 price objective for the company. in a report on Thursday, September 28th. BidaskClub cut Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a report on Thursday, July 27th. Zacks Investment Research cut Pacific Biosciences of California from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Finally, ValuEngine lowered Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 13th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. Pacific Biosciences of California currently has a consensus rating of “Hold” and a consensus target price of $8.93.

Pacific Biosciences of California (NASDAQ PACB) traded up 0.20% during midday trading on Friday, reaching $4.89. The company’s stock had a trading volume of 539,695 shares. Pacific Biosciences of California has a 52 week low of $3.08 and a 52 week high of $9.28. The company’s 50-day moving average is $5.03 and its 200 day moving average is $4.25. The firm’s market capitalization is $565.24 million.

Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.02). Pacific Biosciences of California had a negative net margin of 89.67% and a negative return on equity of 93.31%. The company had revenue of $20.07 million for the quarter, compared to analyst estimates of $23.34 million. During the same quarter in the previous year, the business posted ($0.21) earnings per share. Pacific Biosciences of California’s revenue was down 3.2% on a year-over-year basis. Analysts expect that Pacific Biosciences of California will post ($0.89) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Pacific Biosciences of California (PACB) Getting Favorable News Coverage, Analysis Finds” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Insider Buying and Selling by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Stock Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related stocks with our FREE daily email newsletter.